-
A Study for Patients With Active Crohn’s Disease
The YELLOWSTONE Induction 1 and 2 studies are phase 3, randomized, double-blind, placebo-controlled, multicenter studies that will evaluate the efficacy and safety of ozanimod (also known as RPC1063), an investigational oral medication being studied for individuals with moderately to severely active Crohn’s disease.
-
A Study for Patients With Active Crohn’s Disease
The YELLOWSTONE Induction 1 and 2 studies are phase 3, randomized, double-blind, placebo-controlled, multicenter studies that will evaluate the efficacy and safety of ozanimod (also known as RPC1063), an investigational oral medication being studied for individuals with moderately to severely active Crohn’s disease.
-
A Study for Patients With Active Crohn’s Disease
The YELLOWSTONE Induction 1 and 2 studies are phase 3, randomized, double-blind, placebo-controlled, multicenter studies that will evaluate the efficacy and safety of ozanimod (also known as RPC1063), an investigational oral medication being studied for individuals with moderately to severely active Crohn’s disease.
This website provides information about ozanimod clinical research trials for the treatment of active Crohn’s disease.
